Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics
This survey study (n=2822) examined the prevalence and associations of challenging, difficult, or distressing experiences using classic psychedelics in a subsample of respondents (n=613) who reported lifetime classic psychedelic use. Of those, 59% indicated no challenging experiences, 9% indicated having a difficult experience lasting more than one day, and 2.6% reported seeking medical/psychiatric/psychological assistance.
Authors
- Otto Simonsson
- Peter Hendricks
- Wojciech Osika
Published
Abstract
Previous studies have investigated challenging, difficult, or distressing experiences using classic psychedelics, but little is known about the prevalence and associations of such experiences. Using nationally representative data of the US adult population (N = 2822), this study examined the prevalence and associations of challenging experiences using classic psychedelics, in a subsample of respondents who reported lifetime classic psychedelic use (n = 613). Of the 613 respondents who reported lifetime classic psychedelic use, the majority of them (59.1 %) had never had a challenging, difficult, or distressing experience using a classic psychedelic, but 8.9 % of respondents reported functional impairment that lasted longer than one day. Notably, 2.6 % reported seeking medical, psychiatric, or psychological assistance in the days or weeks following their most challenging, difficult, or distressing experience. In covariate-adjusted regression models, co-use of lithium, co-use of other mood stabilizers, and six set and setting variables (no preparation, disagreeable physical environment, negative mindset, no psychological support, dose was too large, major life event prior to experience) were associated with the degree of difficulty during respondents' most challenging classic psychedelic experience; and co-use of lithium, co-use of other mood stabilizers, and three set and setting variables (negative mindset, no psychological support, major life event prior to experience) were associated with overall risk of harm. In summary, this study provides insight into the prevalence and associations of challenging, difficult, or distressing classic psychedelic experiences. The findings broadly correspond with findings from previous studies and can inform harm reduction efforts and future experimental research designs.
Research Summary of 'Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics'
Introduction
Classic serotonergic (5-HT2A agonist) psychedelics such as psilocybin are increasingly studied for therapeutic potential and generally show a favourable safety profile in controlled trials when combined with psychological support. However, most clinical work has used carefully screened participants in highly structured settings, leaving uncertainty about risks arising from use in broader, naturalistic contexts. Existing guidelines therefore emphasise screening (for example, excluding people taking certain medications such as lithium) and attentiveness to set (psychological state) and setting (physical and social environment) as ways to reduce harm, but population-level data on the prevalence and correlates of challenging, difficult, or distressing psychedelic experiences are limited. Simonsson and colleagues set out to address that gap by conducting exploratory analyses of challenging experiences among lifetime users of classic psychedelics within a nationally representative sample of US adults (with respect to sex, age and ethnicity). The study aimed to estimate prevalence of such experiences, describe their phenomenology and immediate consequences, and examine associations between medication co-use, set and setting variables, and both the intensity of challenging experiences and subsequent risk of harm.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Topics
- Authors
- APA Citation
Simonsson, O., Hendricks, P. S., Chambers, R., Osika, W., & Goldberg, S. B. (2023). Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics. Journal of Affective Disorders, 326, 105-110. https://doi.org/10.1016/j.jad.2023.01.073
References (14)
Papers cited by this study that are also in Blossom
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Schindowski, E. M., Jungwirth, J., Schuldt, A. et al. · EClinicalMedicine (2023)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)
Cohen, S. · Journal of Nervous and Mental Disease (1980)
Strassman, R. J. · Journal of Nervous and Mental Disease (1984)
Gashi, L., Sandberg, S., Pedersen, W. · International Journal of Drug Policy (2021)
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Personality and Individual Differences (2017)
Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)
Show all 14 referencesShow fewer
Simonsson, O., Sexton, J. D., Hendricks, P. S. · Journal of Psychopharmacology (2021)
Milliere, R., Carhart-Harris, R. L., Roseman, L. et al. · Frontiers in Psychology (2018)
Payne, J. E., Chambers, R., Liknaitzky, P. · ACS Pharmacology and Translational Science (2021)
Nayak, S., Gukasyan, N., Barrett, F. S. et al. · Pharmacopsychiatry (2021)
Cited By (20)
Papers in Blossom that reference this study
Oliver, C. R., Luke, D., Evans, J. et al. · Research Square (2026)
Evens, R., Uyar, A., Gosslau, E. et al. · Psychological Medicine (2026)
Dourron, H. M., Bradley, M. K., Copes, H. et al. · International Journal of Mental Health and Addiction (2026)
Goldy, S. P., Sepeda, N. D., Hilbert, S. N. et al. · Psychiatry Research (2026)
Simonsson, O., Hendricks, P. S., Swords, C. M. et al. · Journal of Affective Disorders (2025)
Evans, J., Aixalà, M., Anderson, B. T. et al. · Psychiatric Research & Clinical Practice (2025)
Mathai, D. S., Roberts, D. E., Nayak, S. M. et al. · Journal of Psychedelic Drugs (2025)
McAlpine, R., Kamboj, S. K. · Scientific Reports (2024)
Stroud, J., Rice, C., Orsini, A. et al. · Psychopharmacology (2024)
Calder, A. E., Rausch, B., Liechti, M. E. et al. · Journal of Psychopharmacology (2024)
Show all 20 papersShow fewer
Robinson, O., Evans, J., Luke, D. et al. · Frontiers in Psychology (2024)
Black, J. C., Monte, A. A., Dasgupta, N. et al. · Nature Mental Health (2024)
Weiss, B., Leor Roseman, •., Giribaldi, B. et al. · International Journal of Mental Health and Addiction (2024)
Borkel, L. F., Rojas-Hernández, J., Henríquez-Hernández, L. A. et al. · Expert Review of Clinical Pharmacology (2023)
Evans, J., Robinson, O., Ketzitzidou-Argyri, E. et al. · PLOS ONE (2023)
Simonsson, O., Osika, W., Stenfors, C. U. D. et al. · Psychological Medicine (2023)
Heinzerling, K. G., Sergi, K., Linton, M. et al. · Frontiers in Psychiatry (2023)
Zeifman, R. J., Kettner, H., Pagni, B. A. et al. · Scientific Reports (2023)
Heifets, B. D., Olson, D. E. · Neuropsychopharmacology (2023)
Michael, P., Luke, D., Robinson, O. · Frontiers in Psychology (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.